During the past 12 months, SCYNEXIS's average EPS without NRI Growth Rate was -145.80% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 33.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of SCYNEXIS was 53.70% per year. The lowest was 15.70% per year. And the median was 36.80% per year.
Competitive Comparison of SCYNEXIS's 3-Year EPS without NRI Growth Rate
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SCYNEXIS's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's 3-Year EPS without NRI Growth Rate falls into.
SCYNEXIS 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
SCYNEXIS (NAS:SCYX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
SCYNEXIS 3-Year EPS without NRI Growth Rate Related Terms
Thank you for viewing the detailed overview of SCYNEXIS's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCYX has been successfully added to your